|
Jul 10
|
RBC Capital Maintains a Buy on Biogen (BIIB) With a $208 PT
|
|
Jul 10
|
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
|
|
Jul 10
|
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
|
|
Jul 10
|
Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT
|
|
Jul 8
|
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
|
|
Jul 1
|
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
|
|
Jul 1
|
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
|
|
Jun 30
|
AbbVie to buy Capstan for up to $2.1 billion in immunology push
|
|
Jun 30
|
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market
|
|
Jun 30
|
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
|
|
Jun 28
|
Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials
|
|
Jun 28
|
Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results
|
|
Jun 27
|
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
|
|
Jun 26
|
5 Revealing Analyst Questions From Biogen’s Q1 Earnings Call
|
|
Jun 25
|
Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations
|
|
Jun 25
|
Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics
|
|
Jun 25
|
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
|
|
Jun 25
|
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
|
|
Jun 12
|
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
|
|
Jun 3
|
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
|